Skip to main content

Luminex Says Q2 Revenue Grew 20 Percent as Loss Swings to Profit

NEW YORK (GenomeWeb News) – Luminex today said total second-quarter revenues increased 25 percent as a net loss turned into a profit.
 
Receipts for the three months ended June 30 increased to $13 million from $10.7 million year over year. The company said it generated $5.8 million from the sale of 205 Luminex Systems in the period.
 
R&D costs increased 20 percent to $1.8 million from $1.5 million from the comparable quarter a year ago.
 
Luminex also reported a net income of $271,000 for the second quarter compared to a net loss of $363,000 last year.
 
Luminex had $24 million in cash and cash equivalents as of June 30.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.